AllConferencesCOVID-19MiscellaneousResearchUncategorizedAll Conferences COVID-19 Miscellaneous Research Uncategorized Webcast Mundipharma – July 15th 2020On July 15, from 6 – 7.30 pm GMT, Mundipharma organizes a webinar for pulmonologists and other interested HCP’s on respiratory topics in the focus of interest, such as the… View ArticlePodcast with Dr. Rola on the clinical possibilities of FRIOn July 3rd, Fluidda’s CEO Dr Jan De Backer had a podcast interview with Dr Philippe Rola, president of the critical care unit at the Santa Cabrini Hospital in Montreal,… View ArticleWebinar – Lessons Learned from COVID-19 – Now Available OfflineThis week a very high rated webinar was broadcast where the latest findings on COVID-19 research with FRI-technology was presented by prominent pulmonologists and radiologists from all over the world…. View ArticleWebinar – Lessons learned from the COVID-19 crisisLessons learned from the COVID-19 crisis. This is the title of a webinar Fluidda and Chiesi will broadcast on July 1st at 8 pm CET for interested pulmonologists and other… View ArticleAssessment of small pulmonary blood vessels in COVID-19 patients using HRCTNew publication on FRI: Assessment of small pulmonary blood vessels in COVID-19 patients using HRCT Mounting evidence supports the role of pulmonary hemodynamic alterations in the pathogenesis of COVID-19. Building… View ArticleComparison inhalation with pMDI and pMDI/spacer on drug delivery in the lung using FRI technologyPublished in: Am J Respir Crit Care Med 2020;201:A5689 Authors: J. Suggett1, V. Kushnarev(1) , C. Van Holsbeke (2) , S. Van Steen(2) , B. Mignot(2) 1) Trudell Medical International, London,… View ArticleTheoretical Model of the Pathophysiology of COVID-19 using FRI-data in EMCRIT podcastDuring an EMCRIT podcast last week. Dr. Farid Jalali (Long beach CA) laid out a theoretical framework for the pathophysiology of the lung effects of COVID-19. Take Home Points from this podcast… View ArticleFRI assessment of Glycopyrrolate and FF pMDIs using co-delivery technology in COPDNew published article: FRI assessment of glycopyrrolate and formoterol fumarate pMDI formulations using co-suspension delivery technology in COPD. Understanding lungs and lung diseases has never been more important than in… View ArticleEffectiveness of a new mobile HFCWO device for airway clearance in CF patientsFluidda studied the effectiveness of a new mobile HFCWO device for airway clearance in CF patients. High-frequency chest wall oscillation (HFCWO) is a commonly used airway clearance technique for cystic… View ArticleFull Broadcast – Kathy Ireland InterviewWorldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its viewers with an in-depth opportunity to find solutions to industry problems from some of… View ArticleCOVID-19 – Kathy Ireland InterviewWorldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its viewers with an in-depth opportunity to find solutions to industry problems from some of… View ArticleDiseases and Spirometry – Kathy Ireland InterviewJan De Backer, Fluidda CEO, interviewed in USA television program: Worldwide Business with Kathy Ireland. (Part three) Worldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its… View ArticleInterview AnnouncementLIVE STREAM ANNOUNCEMENT: Fluidda’s CEO will be interviewed on USA television. Dr. Jan De Backer, Fluidda CEO, was recently interviewed about the company’s work on facilitating diagnosis and treatment of… View ArticleOur consortium on COVID-19LET’S TACKLE COVID-19 IN A CONSORTIUM! In an ongoing effort, Fluidda is collecting several batches of HRCT-scans of COVID19-patients to analyze them with their Functional Respiratory Imaging (FRI) technology in… View ArticleWhat is FRI – Kathy Ireland InterviewJan De Backer, Fluidda CEO, interviewed in USA television program Worldwide Business with Kathy Ireland. (Part two) Worldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its… View ArticleOur mission and vision – Kathy Ireland InterviewJan De Backer, Fluidda CEO, interviewed in USA television program Worldwide Business with Kathy Ireland. (Part one) Worldwide Business with Kathy Ireland® is an award-winning business and health program. The show provides its… View ArticleAntwerp biotech company improves lung damage predictability using 3D scans.By Pieter Haeck, reporter Belgian newspaper “De Tijd”. April 7, 2020 What is the prognosis for someone infected with the corona virus? Will the patient deteriorate quickly or not? The… View ArticleNew 3D-printed connector for non-invasive ventilation developed by Materialise and Fluidda.Materialise and Fluidda worked together in the development of a 3D-printed Non-Invasive PEEP Mask to Alleviate Ventilator Shortage For several years. Materialise, a Belgian 3D printing company with one of… View ArticleMedtech goes to war with COVID-19 (DeviceTalks Weekly)In the most recent Device Talk podcast, Jan de Backer, CEO of Fluidda, was interviewed about medtech’s essential role in the escalating war against COVID-19. He explains how Fluidda’s proprietary… View ArticleFDA clears Fluidda’s Broncholab platform for use in Clinical PracticeThe US Food and Drug Administration provided market clearance to Fluidda for its Broncholab platform. Broncholab provides a number of Functional Respiratory Imaging (FRI) parameters to physicians via an online… View ArticleAirway volume measurement with FRI identifies IPF progressionIdiopathic pulmonary fibrosis (IPF) is a progressive disease with unclear etiology. IPF patients decline with heterogeneous trajectories. The ability to determine an individual’s disease course is limited to pulmonary function measurement… View ArticleFluidda’s investigational network of FRI sitesFluidda’s investigational FRI sites are located all over the world, enhancing clinical research with FRI locally. Fluidda is the world leader in the field of Functional Respiratory Imaging. This technique combines HRCT scans,… View ArticleFDA – FRI acknowledged important tool for investigating depositionIn a recent article, the Food and Drug Administration (FDA) mentioned Fluidda’s FRI technology as an important tool to investigate regional drug deposition of the extrathoracic region, especially to measure… View ArticleFRI may be able to help in optimizing lung tumor treatmentFunctional Respiratory Imaging (FRI) may be able to help in optimizing lung tumor treatment. It is not enough to only look at nodule size as one parameter to determine treatment… View ArticleBronchial thermoplasty increases airway volumeIn a recent study, 10 patients with unstable, severe asthma were treated with Bronchial Thermoplasty (BT) of the left lung, while the right lung was used as an internal control. Changes in… View ArticleEffectiveness of a mobile HFCWO device for airway clearanceHigh Frequency Chest Wall Oscillation (HFCWO) is a commonly used airway clearance technique for Cystic Fibrosis (CF) patients. At ERS 2019 in Madrid, a poster was presented on this topic…. View ArticleFiGHT Australian wildfiresFluidda helps firefighters! Because of climate change, there is an increasing number of spontaneous wildfires all over the world, as we are now unfortunately experiencing in Australia. Fluidda, the company… View ArticleThe usage of AI in medical imagingAt the ERS 2019 conference in Madrid, our Director of Research and Development of Fluidda, gave his opinion on how Artificial Intelligence can help to improve the prediction of respiratory… View ArticleHappy Holidays 2019 – 2020Fluidda wishes you happy holidays and an inspiring 2020!PhD thesis on using AI in combination with FRIAt the University of Antwerp, Maarten Lanclus, Research & Development director of Fluidda, successfully defended his thesis on the topic of using Artificial Intelligence (A.I.) in combination with FRI to enhance… View ArticleOur corporate responsibility project – ERS 2019At ERS 2019, Cedric van Holsbeke, Chief Technology Officer of Fluidda talks about Fluidda’s corporate responsibility project. Laptops, previously used for patient training purposes and training of clinical sites, have been donated by… View ArticleDDL Conference 11 – 13 December EdinburghThe Drug Delivery to the Lungs (DDL) Conference provides an annual forum for scientists, academics, clinicians, regulatory and industry specialists involved in developing medicines for inhalation. Fluidda is actively involved in… View ArticleThe effects of particle size in deposition projects – ERS 2019During the ERS 2019 two posters were presented on the deposition of extrafine vs. non-extrafine formulations of different respiratory drugs in different inhalation devices. Both studies were conducted with Functional… View ArticleHow does FRI compare to spirometry?Functional Respiratory Imaging (FRI) parameters can reduce the number of patients required in clinical trials up to sixteen times compared with spirometry while maintaining adequate power and statistical significance. FRI… View ArticleThe value of Fluidda in respiratory clinical research – ERS 2019Prof. W. De Backer, Chairman of the Board of Fluidda nv, was interviewed at the ERS 2019 conference in Madrid about the insights that lead to the founding of the… View ArticleThe advantages of using FRI in clinical trials – ERS 2019Glenn Leemans, Fluidda’s Chief Operative Officer (COO), was interviewed at the ERS 2019 conference in Madrid. In this interview, Glenn explains why Fluidda’s proprietary functional respiratory imaging (FRI) technique can… View ArticleRSNA 2019 – Annual Congress 1st – 6th December ChicagoFluidda will be present at the annual congress of the Radiological Society of North America (RSNA). This year’s congress will take place during 1-6 December in Chicago, Illinois . The RSNA… View ArticleUsing FRI to detect early wildfire exposure on lung developmentDuring the ERS 2019 conference, Fluidda presented the results of a study which investigated that FRI (Functional Respiratory Imaging) parameters can be a sensitive tool to detect early-life wildfire smoke… View ArticleUnderstanding Mucus in Chronic Obstructive Pulmonary Disease (COPD)Mucus plays a major role in Chronic Obstructive Pulmonary Disease (COPD), especially in the Chronic Bronchitis phenotypes. Mucus increases airway resistance making it harder for the patient to breath. At… View ArticleThe highlights of ERS 2019 by Jan De Backer, CEO of FluiddaAt ERS 2019, Jan de Backer, CEO of Fluidda, explains why during the past years, the treatment of lung diseases is shifting from using more common bronchodilatators to more personalized… View ArticleERS 2019 – We are present with our booth and 7 postersFrom September 28 until October 2, Fluidda will exhibit at the annual conference of the European Respiratory Society (ERS) in Madrid, Spain. During this conference, Fluidda will present 7 posters on… View ArticleFluidda will be present at the Annual Drug Discovery & Development Symposium on Pulmonary Vascular DiseaseThis year’s symposium will take place in Paris on July 1-2. Each year the meeting brings leading scientists in the fields of pulmonary vascular disease, right heart failure, and clinical trial… View ArticleFluidda attends the International Conference of Medical imaging with Deep LearningDuring July 8-10 the International Conference of Medical imaging with Deep Learning takes place in London. The FLUIDDA team, specialised in using advanced A.I. algorithms to extract clinically relevant regional… View ArticleBronchial thermoplasty increases airway volume measured by Functional Respiratory Imaging (FRI)In a recently published study (click here for full article) 10 patients with unstable, severe asthma were treated with bronchial thermoplasty of the left lung, while the right lung was used as an… View Article
